Stability of Prednisone in Oral Mix Suspending Vehicle
Author(s): Friciu Mihaela, Plourde Kevin, Leclair Grégoire, Danapoulos Panagiota, Savji Taslim
Issue: Jul/Aug 2015 - Volume 19, Number 4
View All Articles in Issue
Page(s): 337-339
Download in electronic PDF format for $75
Abstract: The stability of prednisone (5 mg/mL) formulated as a suspension in Oral Mix vehicle was evaluated. Oral Mix is a novel oral, dye-free suspending vehicle developed by Medisca Pharmaceutique Inc. for preparation of extemporaneous dosage forms. This drug was chosen based on its high frequency of prescription among the pediatric population. Suspensions were prepared from both pure active and commercial tablets utilizing two different container closures: amber glass bottles and polypropylene syringes (PreciseDose Dispenser Medisca Pharmaceutique Inc.). Formulations were stored at 5°C or 25°C and organoleptic properties, pH, and concentration were evaluated at predetermined time points up to 90 days. Validated stability-indicating high-performance liquid chromatography methods were developed. Beyond-use date was evaluated by statistical analysis of the overall degradation trend. Prednisone was stable for at least 90 days at 25°C. No changes in organoleptic properties or pH were observed for either of the formulations, and the global stability was roughly equivalent and sometimes superior to the stability of the same drugs in other previously used vehicles. Thus, Oral Mix was found to be a suitable dye-free vehicle for extemporaneous formulations.
Related Keywords:
prednisone, oral suspension vehicle, Oral Mix, storage, stability, children, excipients
Related Categories:
EXCIPIENTS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, ALLERGY/IMMUNOLOGY/INFLAMMATION
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Stability of Prednisone in Oral Mix Suspending Vehicle
Friciu Mihaela, Plourde Kevin, Leclair Grégoire, Danapoulos Panagiota, Savji Taslim
|
Jul/Aug 2015
Pg. 337-339
|
Oral Liquid Vehicles, Featured Excipient:
Allen Loyd V Jr
|
Jan/Feb 2001
Pg. 65-67
|
Prednisone 5 mg/mL ir Oral Mix Suspension
Allen Loyd V Jr
|
Nov/Dec 2018
Pg. 497
|
Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations
Visser J Carolina, ten Seldam Inge E J, van der Linden Isabella J, Hinrichs Wouter L J, Veenendaal Reinier F H, Dijkers Eli C F, Woerdenbag Herman J
|
May/Jun 2018
Pg. 247-251
|
Stability of Allopurinol in Extemporaneously Compounded Oral Suspensions with Oral Mix and Oral Mix SF
Friciu Mihaela, Cull Erica, Leclair Grégoire
|
Sep/Oct 2024
Pg. 408-412
|
Women's Oral Health: Is There a Hormonal Link?
Preckshot John
|
Jan/Feb 2004
Pg. 10-14
|
Clonidine 0.01-mg/mL in Oral Mix and Oral Mix SF Suspension
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 44
|
Metronidazole 50-mg/mL in Oral Mix and Oral Mix SF Suspension
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 47
|
Dapsone 2-mg/mL in Oral Mix or Oral Mix SF Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 415
|
Dexamethasone 1-mg/mL in Oral Mix or Oral Mix SF Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 416
|
Pyridoxine Hydrochloride 25 mg/mL in Oral Mix and Oral Mix SF Suspension
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 505
|
Stability of Verapamil Hydrochloride in SyrSpend SF Compared to Sorbitol Containing Syrup and Suspending Vehicles
Voudrie Mark A, Alexander Bridget, Allen D Brett
|
May/Jun 2011
Pg. 255-258
|
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Kabiche Djamila, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
|
Mar/Apr 2017
Pg. 160-163
|
Gabapentin 100 mg/mL in Oral Mix or Oral Mix SF Suspension
Allen Loyd V Jr
|
May/Jun 2018
Pg. 235
|
Restructuring the Art of Health by Pharmacists: Formulation Designs with Oral Vehicles--Teaching Pharmacy Students
Benischek Rita
|
Mar/Apr 2017
Pg. 105-108
|
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Nahata Milap C
|
May/Jun 2016
Pg. 247-249
|
Basics of Compounding: Vehicles for Compounded Oral Liquid Medications: A Review
Cutaia Kara, Chablani Lipika, Zhao Fang
|
Nov/Dec 2018
Pg. 480-489
|
Hydroxychloroquine Sulfate 25 mg/mL in Oral Mix or Oral Mix SF
Allen Loyd V Jr
|
Nov/Dec 2017
Pg. 494
|
Naproxen 25 mg/mL in Oral Mix or Oral Mix SF
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 54
|
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
|
Jul/Aug 2017
Pg. 322-329
|
Return to Top |